Ask AI
ProCE Banner Activity

CME

From IV to SC: Multidisciplinary Strategies for Transforming ICI Delivery to Enhance Patient-Centered Care and Ensure Equitable Access

Text Module

Read this expert-guided text module to gain a better understanding of the clinical evidence, recent FDA approvals, and expert recommendations for the integration of subcutaneous immune checkpoint inhibitors for the treatment of patients with cancer.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: June 25, 2025

Expiration: December 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and ProCE, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Partners

Practicing Clinicians Exchange, LLC

ProCE Banner

ProCE, LLC

ProCE Banner

Target Audience

This activity is intended for medical oncologists, urologists, dermatologists, surgical oncologists, thoracic surgeons, and other healthcare professionals caring for cancer patients receiving immune checkpoint inhibitors. 

Program Learning Goal

This activity aims to improve learners' knowledge, competence, and performance in enhancing the comprehensive care of patients with cancer receiving immune checkpoint inhibitor therapies.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Evaluate the benefits and challenges of IV vs SQ ICI routes of administration focusing on patient convenience, HRQoL improvements, healthcare resource utilization, and patient safety

  • Compare efficacy and safety evidence for SQ and IV ICI therapies in patients with cancer across different tumor types and the potential impact of novel delivery systems

  • Integrate comprehensive knowledge of SQ ICI therapies, focusing on effective administration, monitoring for safety and drug-related complications, and coordinating complex treatment regimens to optimize patient-centric care

  • Implement effective multidisciplinary team processes to optimize the implementation of SC administration of ICI therapies into clinical practice based on the latest evidence and individual healthcare system considerations  

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Patrick Forde, MD, PhD: researcher (paid to institution): AstraZeneca, BioNTech, Bristol Myers Squibb, Novartis, Regeneron; consultant: Amgen, Ascendis, AstraZeneca, BioNTech, Bristol Myers Squibb, Curevac, G1, Genelux, Genentech, Gritstone, F Star, Flame, Fosun, Iteos, Janssen, Merck, Novartis, Regeneron, Sanofi, Synthekine, Tavotek, Teva.

Saby George, MD, FACP: consultant/advisor/speaker: AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, GlaxoSmithKline, Jonnson & Johnson, Merck Sharp & Dohme, Novartis.

Evan J. Lipson, MD: consultant/advisor/speaker: Bristol Myers Squibb, HUYA Bioscience International, Immunocore, InstilBio, IO Biotech, Merck, Merck KGaA, Novartis, OncoSec, Pfizer, Regeneron, Sun; researcher: Bristol Myers Squibb, Haystack; individual publicly traded stock/stock options: Iovance.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 25, 2025, through December 24, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.